Dyadic Q2 net loss narrows to $2.15M; positive Phase 1 safety data for COVID booster DYAI-100

DYADIC INTERNATIONAL INC

Net loss $2.15M (-$0.07/sh) vs -$3.29M (-$0.12/sh) YoY; revenue $837K up from $659K.
Positive interim Phase 1 data: no major safety issues, immune response at both low and high doses of DYAI-100.
Cash $10.2M at June 30, 2023, down from $12.7M at Dec 31, 2022.
New fully funded collaborations: Top 5 pharma for vaccine antigen, EDCL in Bangladesh, Fermbox for alternative proteins.
Developed animal-free recombinant serum albumin; structurally equivalent to animal-derived product.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DYADIC INTERNATIONAL INC reported financial results for the second quarter of 2023.

Period: the second quarter of 2023
Result: reported results

Exact text from the filing

On August 9, 2023, Dyadic International, Inc. ("Dyadic") issued a press release announcing its results for the quarter ended June 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-022782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.